AVROBIO Receives Rare Pediatric Disease Designation From The U.S. FDA For AVR-RD-05, A Gene Therapy For Mucopolysaccharidosis Type II Or Hunter Syndrome by | Nov 3, 2021 | Uncategorized | 0 comments Meritas Media Team Submit a Comment Cancel replyYour email address will not be published. Required fields are marked *Comment Name * Email * Website Save my name, email, and website in this browser for the next time I comment.
Recent Comments